Design of Tissue-specific Regulatory Cassettes for High-level rAAV-mediated Expression in Skeletal and Cardiac Muscle
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Systemic delivery of recombinant adeno-associated virus (rAAV) 6 vectors mediates efficient transduction of the entire striated musculature, making this an attractive strategy for muscle gene therapy. However, owing to widespread transduction of non-muscle tissues, optimization of this method would benefit from the use of muscle-specific promoters. Most such promoters either lack high-level expression in certain muscle types or are too large for inclusion in rAAV vectors encoding microdystrophin. Here, we describe novel regulatory cassettes based on enhancer/promoter regions of murine muscle creatine kinase (CK) and alpha-myosin heavy-chain genes. The strongest cassette, MHCK7 (770 bp), directs high-level expression comparable to cytomegalovirus and Rous sarcoma virus promoters in fast and slow skeletal and cardiac muscle, and low expression in the liver, lung, and spleen following systemic rAAV6 delivery in mice. Compared with CK6, our previous best cassette, MHCK7 activity is approximately 400-, approximately 50-, and approximately 10-fold higher in cardiac, diaphragm, and soleus muscles, respectively. MHCK7 also directs strong microdystrophin expression in mdx muscles. While further study of immune responses to MHCK7-regulated microdystrophin expression is needed, this cassette is not active in dendritic cell lines. MHCK7 is thus a highly improved regulatory cassette for experimental studies of rAAV-mediated transduction of striated muscle.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Relative tissue-specific expression of two gRNAs for CRISPR/Cas gene editing in myotubes was achieved by linking a muscle-specific MHCK7 promoter (pol II) with gRNA-linked self-cleaving ribozyme sequences derived of Hepatitis delta virus (HDV) and a Hammerhead (HH) sequence [134-137].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [135]
Citations
Cites
Three myosin heavy chain isoforms in type 2 skeletal muscle fibres
Schiaffino, S., Gorza, L., Sartore, S., Saggin, L., Ausoni, S., Vianello, M., Gundersen, K., & LØmo, T. (1989) · Journal of Muscle Research and Cell Motility · doi:10.1007/bf01739810 · Cited by 954
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
Self-citationKessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., & Byrne, B. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14082 · Cited by 614
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J., & Xiao, X. (2005) · Nature Biotechnology · doi:10.1038/nbt1073 · Cited by 608
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Bottinelli, R., Schiaffino, S., & Reggiani, C. (1991) · The Journal of Physiology · doi:10.1113/jphysiol.1991.sp018617 · Cited by 486
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006) · Circulation Research · doi:10.1161/01.res.0000237661.18885.f6 · Cited by 406
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Cited by
Items 101–200 of 232
Sun, B., Li, S., Bird, A., Yi, H., Kemper, A. R., Thurberg, B. L., & Koeberl, D. D. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1511 · Cited by 27
Bengtsson, N. E., Tasfaout, H., Hauschka, S. D., & Chamberlain, J. S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.003 · Cited by 29
Self-citationAAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial
Butterfield, R. J., Shieh, P. B., Li, H., Binks, M. H., McDonnell, T. G., Ryan, K. A., Delnomdedieu, M., Belluscio, B. A., Neelakantan, S., Lévy, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03750-3 · Cited by 28
“Preclinical studies have shown that this vector produces a miniaturized but functional form of dystrophin (hereafter referred to as ‘mini-dystrophin’) 12,13 , which is expressed in cardiac and skeletal muscle.”
In vivo applications and toxicities of AAV-based gene therapies in rare diseases
Zhao, Q., Peng, H., Ma, Y., Yuan, H., & Jiang, H. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03893-z · Cited by 33
“SRP-9001 (AAVrh74-hMHCK7) is driven by a synthetic MHCK7 promoter, consisting of a creatine kinase (MCK) promoter fused with MCK and an α-myosin heavy chain complex (α-MHC) enhancer, promoting high expression levels in skeletal and cardiac muscle [62].”
Engineered bacterial voltage-gated sodium channel platform for cardiac gene therapy
Nguyen, H. X., Wu, T., Needs, D., Zhang, H., Perelli, R. M., DeLuca, S., Yang, R., Pan, M., Landstrom, A. P., Henriquez, C. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28251-6 · Cited by 26
Cardiac gene therapy: are we there yet?
Matkar, P. N., Leong-Poi, H. M., & Singh, K. K. (2016) · Gene Therapy · doi:10.1038/gt.2016.43 · Cited by 31
AAV6 Vector Production and Purification for Muscle Gene Therapy
Halbert, C. L., Allen, J. M., & Chamberlain, J. S. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7374-3_18 · Cited by 28
“muscle-specific gene regulatory cassettes (RCs) [9].”
Self-citationPark, J. C., Wicki, J., Knoblaugh, S. E., Chamberlain, J. S., & Lee, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124914 · Cited by 28
“Furthermore, muscle-specific promoters have been developed to restrict expression to target muscle cells and potentially reduce the possibility of an undesirable immune response [19].”
BackgroundSelf-citationMack, D. L., Guan, X., Wagoner, A. L., Walker, S. J., & Childers, M. K. (2014) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000000141 · Cited by 25
Strategies for Skeletal Muscle Targeting in Drug Discovery
Ebner, D. C., Bialek, P., El‐Kattan, A. F., Ambler, C. M., & Tu, M. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140929095755 · Cited by 23
Transcriptional Targeting Approaches in Cardiac Gene Transfer Using AAV Vectors
Schröder, L. C., Frank, D., & Müller, O. J. (2023) · Pathogens · doi:10.3390/pathogens12111301 · Cited by 23
Hagg, A., Colgan, T. D., Thomson, R. E., Qian, H., Lynch, G. S., & Gregorevic, P. (2016) · Scientific Reports · doi:10.1038/srep23042 · Cited by 27
Self-citationGandhi, S., Sweeney, H. L., Hart, C. C., Han, R., & Perry, C. G. R. (2024) · Cells · doi:10.3390/cells13141168 · Cited by 31
Stephenson, A. A., Nicolau, S., Vetter, T. A., Dufresne, G., Frair, E. C., Sarff, J., Wheeler, G. L., Kelly, B., White, P., & Flanigan, K. M. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.009 · Cited by 23
Buscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 23
Strash, N., DeLuca, S., Carattini, G. L. J., Heo, S. C., Gorsuch, R. A., & Bursac, N. (2021) · eLife · doi:10.7554/elife.65512 · Cited by 19
Léger, A., Guiner, C. L., Nickerson, M. L., McGee, K., Ferry, N., Moullier, P., Snyder, R. O., & Penaud‐Budloo, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020881 · Cited by 23
“data obtained in mice after single-stranded AAV6 injection [50].”
BackgroundMicro-dystrophin Gene Therapy Partially Enhances Exercise Capacity in Older Adult mdx Mice
Rodgers, B. D., Bishaw, Y. M., Kagel, D. R., Ramos, J. N., & Maricelli, J. W. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.015 · Cited by 24
Marshall, J. P. S., Estévez, E., Kammoun, H. L., King, E. J., Bruce, C. R., Drew, B. G., Qian, H., Iliades, P., Gregorevic, P., Febbraio, M. A., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13319 · Cited by 19
“(CMV) promoter or the muscle creatine kinase (MCK) promoter, which targets all striated muscle including cardiac muscle.(24) Therefore, by using this construct, any findings would be restricted to the role of”
BackgroundSelf-citationZygmunt, D. A., Xu, R., Jia, Y., Ashbrook, A., Menke, C., Shao, G., Yoon, J. H., Hamilton, S., Pisharath, H., Bolon, B. N., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.005 · Cited by 21
“The MHCK7 promoter induced more GALGT2 gene expression in skeletal muscle than the MCK promoter did (Figures 5A and 5B), consistent with previous studies.(31)”
ResultHeller, K. N., Montgomery, C. L., Shontz, K. M., Clark, K. R., Mendell, J. R., & Rodino‐Klapac, L. R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.062 · Cited by 24
Liu, S., Chowdhury, E. A., Xu, V., Jerez, A., Mahmood, L., Ly, B. Q., Le, H. K., Nguyen, A., Rajwade, A., Meno‐Tetang, G. M. L., et al. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.005 · Cited by 19
What’s new and what’s next for gene therapy in Pompe disease?
Roger, A. L., Sethi, R., Huston, M. L., Scarrow, E. R., Bao-Dai, J., Lai, E., Biswas, D. D., Haddad, L. E., Strickland, L. M., Kishnani, P. S., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2067476 · Cited by 20
Seo, Y.-E., Baine, S. H., Kempton, A. N., Rogers, O. C., Lewis, S., Adegboye, K., Haile, A., Griffin, D. A., Peterson, E. L., Pozsgai, E. R., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.01.004 · Cited by 18
“To drive expression in muscle cells, SRP-9005 contains an MHCK7 promoter, an optimized version of the muscle-specific MCK promoter with enhanced cardiac expression.(28) The MHCK7 promoter has been shown previously to drive robust expression in both skeletal muscle and heart.”
BackgroundCurrent avenues of gene therapy in Pompe disease
Leon‐Astudillo, C., Trivedi, P. D., Sun, R. C., Gentry, M. S., Fuller, D. D., Byrne, B. J., & Corti, M. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001187 · Cited by 24
“Conversely, a variety of muscle specific promoters are utilized to restrict expression to striated muscle, showing minimal expression in nonmuscle tissues and potentially reducing the immune response to the transgene [28].”
BackgroundViral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 24
CRISPR Activation Enhances In Vitro Potency of AAV Vectors Driven by Tissue-Specific Promoters
McDougald, D. S., Duong, T. T., Palozola, K. C., Marsh, A., Papp, T. E., Mills, J. A., Zhou, S., & Bennett, J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.03.004 · Cited by 21
“These regulatory elements provide specificity to the cell targets of interest in vivo but can display poor activity when applied to cell-based systems.(2,3) In the context of retinal gene transfer, several promoter sequences enable selective and stable gene expression patterns in various cell types.”
BackgroundEckenfelder, A., Tordo, J., Babbs, A., Davies, K. E., Goyenvalle, A., & Danos, O. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.24 · Cited by 17
Kawakami, E., Kinouchi, N., Adachi, T., Ohsawa, Y., Ishimaru, N., Ohuchi, H., Sunada, Y., Hayashi, Y., Tanaka, E. I., & Noji, S. (2011) · Development Growth & Differentiation · doi:10.1111/j.1440-169x.2010.01221.x · Cited by 18
Engineered myovascular tissues for studies of endothelial/satellite cell interactions
Broer, T., Tsintolas, N., Purkey, K., Hammond, S., DeLuca, S., Wu, T., Gupta, I., Khodabukus, A., & Bursac, N. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.09.020 · Cited by 17
Xu, R., Jia, Y., Zygmunt, D. A., Cramer, M. L., Crowe, K. E., Shao, G., Maki, A. E., Guggenheim, H. N., Hood, B. C., Griffin, D. A., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.002 · Cited by 16
Zygmunt, D. A., Singhal, N., Kim, M.-L., Cramer, M. L., Crowe, K. E., Xu, R., Jia, Y., Adair, J., Martinez-Pena y Valenzuela, I., Akaaboune, M., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00426-16 · Cited by 15
“The MHCK7 promoter is a skeletal muscle- and heart-specific promoter designed by Hauschka and colleagues (62), while rAAVrh74, or rhesus serotype 74, is a viral AAV capsid similar to rAAV8 (91).”
BackgroundGenetic strategies for therapy of Duchenne muscular dystrophy
Łoboda, A., Chamberlain, J. S., & Dulak, J. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102759 · Cited by 20
“125,127 AAV-mediated μ Dys expression was also effective in DMD dogs.”
Self-citationMartin, P. T., Zygmunt, D. A., Ashbrook, A., Hamilton, S., Packer, D., Birch, S. M., Bettis, A. K., Balog-Alvarez, C. J., Guo, L., Nghiem, P. P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248721 · Cited by 15
“GALGT2 vectors typically take 3–4 weeks after muscle transduction to achieve full gene expression [36], we chose to use the stronger MHCK7 [67, 68] promoter instead of the MCK (CK7-like [69]) promoter, which is currently being tested in a phase 1/2a DMD clinical trial using rAAVrh74.”
BackgroundMethodPolymers for Improving the In Vivo Transduction Efficiency of AAV2 Vectors
Moulay, G., Boutin, S., Masurier, C., Scherman, D., & Kichler, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015576 · Cited by 15
“It has been previously shown that tail vein injection in mice of an AAV vector coding for a reporter gene under the control of the muscle creatine kinase (MCK) promoter results in strong expression in muscles while expression in nonmuscle tissues remains #4% of the highest activity seen in most skeletal muscles [22].”
BackgroundMethodAAV-NRIP gene therapy ameliorates motor neuron degeneration and muscle atrophy in ALS model mice
Chen, H.-H., Yeo, H.-T., Huang, Y.-H., Tsai, L.-K., Lai, H.-J., Tsao, Y.-P., & Chen, S.-L. (2024) · Skeletal Muscle · doi:10.1186/s13395-024-00349-z · Cited by 14
“To mitigate immune responses to the targeted protein, muscle-specific regulatory cassettes that restrict expression to skeletal and cardiac muscles can be employed [72, 73].”
BackgroundBaine, S. H., Wier, C., Lemmerman, L. R., Cooper-Olson, G., Kempton, A. N., Haile, A., Endres, J., Fedoce, A., Nesbit, E., Rodino‐Klapac, L. R., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.013 · Cited by 14
Packer, D., & Martin, P. T. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.004 · Cited by 17
Electrophysiological analysis of healthy and dystrophic 3-D bioengineered skeletal muscle tissues
Nguyen, C. T., Ebrahimi, M., Gilbert, P. M., & Stewart, B. A. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00049.2021 · Cited by 15
Yoo, J., Kohlbrenner, E., Kim, O., Hajjar, R. J., & Jeong, D. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3060 · Cited by 13
Muscle Fiber Type-Predominant Promoter Activity in Lentiviral-Mediated Transgenic Mouse
Suga, T., Kimura, E., Morioka, Y., Ikawa, M., Li, S., Uchino, K., Uchida, Y., Yamashita, S., Maeda, Y., Chamberlain, J. S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016908 · Cited by 13
“As the muscle creatine kinase gene (CK6) promoter, a musclespecific promoter [25], has fiber-type-dependent activity in murine skeletal muscle when tested in AAV vectors [26,27], we”
BackgroundSelf-citationOptogenetic Engineering of Atrial Cardiomyocytes
Feola, I., Teplenin, A. S., de Vries, A. A. F., & Pijnappels, D. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3512-3_22 · Cited by 13
Crowe, K. E., Zygmunt, D. A., Heller, K., Rodino-Klapac, L., Noguchi, S., Nishino, I., & Martin, P. T. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200575 · Cited by 18
Klimchak, A. C., Sedita, L. E., Rodino‐Klapac, L. R., Mendell, J. R., McDonald, C. M., Gooch, K. L., & Malone, D. C. (2023) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2023.2216518 · Cited by 16
“After the benefit discount rate was reduced to reflect the approach used in other countries that future benefits should not be discounted at the same rate as costs, the estimated value was >$5.1 M at a WTP threshold of $500,000/evLYG [82,83].”
BackgroundMethodInfluentialSherlock, S. P., Lévy, D., McIntosh, A., Shieh, P. B., Smith, E. C., McDonnell, T. G., Ryan, K. A., Delnomdedieu, M., Binks, M. H., Lal, A. K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.031 · Cited by 14
Vermeire, G., Smidt, E. D., Geukens, N., Williams, J. A., Declerck, P. J., & Hollevoet, K. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.105 · Cited by 14
Sun, B., Li, S., Bird, A., & Koeberl, D. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.109 · Cited by 12
Skeletal Muscle Metabolism in the Pathology and Treatment of Type 1 Diabetes
Mann, C., Ayuso, E., Anguela, X. M., & Bosch, F. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790883435 · Cited by 19
Lu, M., Lin, Y., Kuo, H., Cai, W., Ye, Q., Zhao, L., & Hu, W. (2024) · Biotechnology Journal · doi:10.1002/biot.202400051 · Cited by 12
Laminin-111 Improves the Anabolic Response to Mechanical Load in Aged Skeletal Muscle
Garg, K., Mahmassani, Z. S., Dvoretskiy, S., Valero, M. C., Huntsman, H. D., Lapp, S., Wu, Y., Hauschka, S. D., Burkin, D. J., & Boppart, M. D. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa308 · Cited by 12
“(19), bred and aged to 6–12 (adult) or 24 months (aged) (n = 3–5).”
Self-citationWinbanks, C. E., Beyer, C., Qian, H., & Gregorevic, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051627 · Cited by 11
“The CK6 promoter is considerably less potent in its ability to drive reporter gene expression in skeletal muscle than the CMV promoter [20].”
BackgroundMethodSelf-citationBlain, M., Zeng, Y., Bendjelloul, M., Hallauer, P. L., Kumar, A., Hastings, K. E. M., Karpati, G., Bernard Massie, B., & Gilbert, R. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.208 · Cited by 11
“Only a few muscle-specific promoters as strong as or better than CMV have been reported in the literature (Li et al., 1999; Salva et al., 2007; Wang et al., 2008).”
BackgroundBanks, G. B., Chamberlain, J. S., & Odom, G. L. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1009179 · Cited by 10
“We also note that our original hinge2-μDys[75, 76] displayed stable expression for up to one year in DMD patients[77], and that a different μDys vector, rAAV6-CK8e-μDys5, showed stable expression in all striated muscles for more than 27 months in mdx mice [78].”
BackgroundSelf-citationRodgers, B. D., Herring, S. K., Carias, D. R., Chen, J., & Rocha, A. G. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.007 · Cited by 10
Asher, D. R., Dai, D., Klimchak, A. C., Sedita, L. E., Gooch, K. L., & Rodino‐Klapac, L. R. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.002 · Cited by 11
“The MHCK7 promoter, comprising an a-myosin heavy chain (a-MHC) enhancer and amuscle creatine kinase (MCK) enhancer/promoter region, induces high transgene expression in skeletal and cardiac muscle.(75) It is therefore being used in the development of therapies for certain LGMD subtypes (including LGMD2B [dysferlinopat…”
BackgroundMcMurphy, T. B., Park, A., Heizer, P. J., Bottenfield, C., Kurasawa, J. H., Ikeda, Y., & Doran, M. R. (2024) · Scientific Reports · doi:10.1038/s41598-024-75698-2 · Cited by 11
Defective BVES-mediated feedback control of cAMP in muscular dystrophy
Li, H., Wang, P., Zhang, C., Zuo, Y., Zhou, Y., & Han, R. (2023) · Nature Communications · doi:10.1038/s41467-023-37496-8 · Cited by 11
Imai, T., Miyai, M., Nemoto, J., Tamai, T., Ohta, M., Yagi, Y., Nakanishi, O., Mochizuki, H., & Nakamori, M. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq2005 · Cited by 10
Gentherapien für neuromuskuläre Erkrankungen
Saffari, A., Weiler, M., Hoffmann, G. F., & Ziegler, A. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0761-z · Cited by 11
Systemic AAV9.BVES delivery ameliorates muscular dystrophy in a mouse model of LGMDR25
Bailin, P. L., Wang, P., Hsu, E., Pinckard, K. M., Stanford, K. I., & Han, R. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.012 · Cited by 10
Strash, N., DeLuca, S., Carattini, G. L. J., Chen, Y., Wu, T., Helfer, A., Scherba, J. C., Wang, I., Jain, M., Naseri, R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adh2598 · Cited by 10
“To ensure CM-specific transgene expression, we generated lentiviruses (LVs) in which the muscle-specific MHCK7 (chimeric α - MHC and murine creatine kinase) promoter ( 45 ) drove expression of mCherry control (Ctrl) or caBRAF- 2A-mCherryNLS (fig.”
MethodRobert, M., Lin, Y., Bendjelloul, M., Zeng, Y., Dessolin, S., Broussau, S., Larochelle, N., Nalbantoglu, J. N., Massie, B., & Gilbert, R. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2675 · Cited by 10
“Among the most efficient of these musclespecific promoters is a battery of synthetic promoters made by the random assembly of cis-acting myogenic regulatory elements linked to the minimal promoter of skeletal a-actin [4], the MHCK7 promoter, constructed by ligating the a-myosin heavy chain enhancer to the muscle creat…”
BackgroundLiu, M., Cook, E., Dai, Y., Ehlert, E., du Plessis, F., Lubelski, J., Sleczka, B. G., Shipkova, P. A., Li, Z., Gamse, J. T., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101411 · Cited by 9
Li, N., & Song, Y. (2022) · Genes · doi:10.3390/genes13112021 · Cited by 12
“MHCK7 promoter (~770 bp), a novel regulatory cassette based on enhancer/promoter regions of murine muscle creatine kinase (CK) and α-myosin heavy-chain genes, can direct high-level expression comparable to cytomegalovirus and Rous sarcoma virus promoters in fast and slow skeletal and cardiac muscle, and low expression…”
BackgroundMethodDevelopment of Assays to Measure GNE Gene Potency and Gene Replacement in Skeletal Muscle
Zygmunt, D. A., Lam, P. M. W., Ashbrook, A., Koczwara, K. E., Lek, A., Lek, M., & Martin, P. T. (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221596 · Cited by 10
Wu, J., Hua, Y., Zheng, Y., Liu, X., & Li, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13081994 · Cited by 7
“The chimeric MHCK7 promoter—a fusion of MCK and α -myosin heavy chain enhancer elements—achieves superior specificity across myofiber subpopulations and cardiac tissue while reducing hepatic off-target expression, enabling its deployment in multiple clinical-stage microdystrophin trials [69,70].”
Ahmadi, E., Ravanshad, M., Xie, J., Panigrahi, R., Jubbal, S. S., Guru, S. K., Guangping, G., Ziyaeyan, M., & Fingeroth, J. D. (2021) · Virology Journal · doi:10.1186/s12985-021-01695-w · Cited by 7
“Genes, including gene regulatory products engineered to eliminate only tumor cells, can be introduced into the AAV genome [20].”
BackgroundEfficacy and muscle safety assessment of fukutin-related protein gene therapy
Benasutti, H., Maricelli, J. W., Seto, J. T., Hall, J. K., Halbert, C. L., Wicki, J., Huesgen, L., Purvis, N., Regnier, M., Lin, D. C., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.022 · Cited by 7
“The resulting DNA fragment was digested with HpaI and AgeI and ligated into an AAV backbone vector containing a muscle-specific CK8e promoter and synthetic poly(A) tail as described previously.(41) Briefly, a custom AAV transfer plasmid containing the previously described muscle-specific CK8e regulator cassette, a 1,4…”
MethodSelf-citationNing, K., Zhang, X. J., Feng, Z., Hao, S., Küz, Ç. A., Cheng, F., Park, S. Y., McFarlin, S., Engelhardt, J. F., Yan, Z., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101115 · Cited by 8
A compact unc45b‐promoter drives muscle‐specific expression in zebrafish and mouse
Rudeck, S., Etard, C., Khan, M. M., Rottbauer, W., Rudolf, R., Strähle, U., & Just, S. (2016) · genesis · doi:10.1002/dvg.22953 · Cited by 7
“Efforts have been made to shorten the MCK promoter, giving rise to the dMTK (509 bp) or tMCK (720 bp) promoter that show skeletal muscle-specific expression (Yue et al., 2015) and the MHCK7 (770 bp) promoter that drives cardiac and skeletal muscle expression (Salva et al., 2007).”
BackgroundEvans, V. C., Graham, I. R., Athanasopoulos, T., Galley, D. J., Jackson, C. L., Simons, J. P., Dickson, G., & Owen, J. S. (2010) · Metabolism · doi:10.1016/j.metabol.2010.04.015 · Cited by 6
“This can be minimized by using a muscle-specific promoter to prevent expression in antigen-presenting cells (and new regulatory cassettes promise high long-term transgene expression [52]) or by engineering AAV capsids to restrict tissue tropism [8,53].”
BackgroundMeng, J., Moore, M., Counsell, J. R., Muntoni, F., Popplewell, L. J., & Morgan, J. E. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.015 · Cited by 6
“25 June 2 the diaphragm,(89) and the MHCK7 promoter is more active in the mouse soleus muscle than the quadriceps and gastrocnemius, as it is more highly expressed in slow (MyHC type I) and fast oxidative (MyHC type IIa) fibers.(90) It should be noted that the mouse TA muscle (the recipient muscle for our cell injecti…”
BackgroundGene-Therapy Delivery Strategies in Cardiology
Müller, O. J., Ksienzyk, J., & Katus, H. A. (2008) · Future Cardiology · doi:10.2217/14796678.4.2.135 · Cited by 7
“α-myosin heavy-chain/creatine kinase promoter AAV-6 Microdystrophin Intravenous Adult mice [52]”
BackgroundDose escalation pre-clinical trial of novel DOK7-AAV in mouse model of DOK7 congenital myasthenia
Cossins, J., Kozma, I., Canzonetta, C., Hawkins, A., Beeson, D., Sepulveda, P. V., & Dong, Y. Y. (2024) · Brain Communications · doi:10.1093/braincomms/fcaf046 · Cited by 6
Development of an AAV-delivered microRNA gene therapy for myotonic dystrophy type 1
Tomassy, G. S., Fan, W., Cao, S., Luo, Z., Magli, A., Zhang, T., Boyle, K., Jackson, R., Richards, B., Liu, D., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.050 · Cited by 7
“Forty-eight hours later, we compared the luciferase activity of these promoters to the ubiquitous CAG promoter and to the MH, 26 MHCK7, 27 and sk-CRM4/Des 24 promoters (Figure 1), which have previously been shown to have high activity in muscle cells.”
Optogenetic Control of Muscles: Potential Uses and Limitations
Cohen, E. M., Knapman, F. L., & Bilston, L. E. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.236 · Cited by 5
Potter, R. A., Griffin, D. A., Heller, K. N., Mendell, J. R., & Rodino‐Klapac, L. R. (2023) · Biology Open · doi:10.1242/bio.059797 · Cited by 4
“(University of Washington, Seattle, WA, USA) (Salva et al., 2007).”
BackgroundMethodInfluentialHimeda, C. L., Jones, T. I., & Jones, P. L. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.041 · Cited by 4
Self-citationGene therapy for atrial fibrillation
Mo, W., & Donahue, J. K. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.09.004 · Cited by 5
Rapti, K., Hajjar, R. J., & Weber, T. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-891-7_12 · Cited by 4
Lu, Q. L., Zhao, S., & Blaeser, A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.051 · Cited by 3
Shieh, P. B., Proud, C. M., Diamond, T., Chapin, C. A., Ahmad, J., Salama, A. D., Bönnemann, C. G., Soslow, J. H., Byrne, B. J., Veerapandiyan, A., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342261423168 · Cited by 10
Bianchi, M., Rossi, L., Pierigè, F., Angeli, P. D., Aliano, M. P., Carducci, C., Carlo, E. D., Pascucci, T., Nardecchia, F., Leuzzi, V., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.007 · Cited by 5
Broer, T., Tsintolas, N., Hammond, S., Helfer, A., Lee, J., Purkey, K., DeLuca, S., Khodabukus, A., & Bursac, N. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404695 · Cited by 3
Genome Editing for Neuromuscular Diseases
Ousterout, D. G., & Gersbach, C. A. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-3509-3_4 · Cited by 4
Description of muscle disease – general aspects
Karpati, G. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511674747.012 · Cited by 3
Hunting for a cure: The therapeutic potential of gene therapy in Duchenne muscular dystrophy
Hashim, H. Z., Abdullah, S. T. C., Sulaiman, W. A. W., Hoo, F. K., & Basri, H. (2014) · Tzu Chi Medical Journal · doi:10.1016/j.tcmj.2014.02.002 · Cited by 3
“It appears to have high level of expression selectivity in the desired muscle tissues [36].”
BackgroundDesign of Muscle Gene Therapy Expression Cassette
Lai, Y., & Duan, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_8 · Cited by 3
Lam, P. M. W., Zygmunt, D. A., Ashbrook, A., Bennett, M., Vetter, T. A., & Martin, P. T. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.028 · Cited by 2
EZH1 as a key mediator of exercise-induced H3K27me3 and H3K4me3 in mouse skeletal muscle
Shimizu, J., Horii, N., Ono, Y., & Kawano, F. (2024) · Advanced Exercise and Health Science · doi:10.1016/j.aehs.2024.11.002 · Cited by 2
Gene Therapy of Skeletal Muscle Disorders Using Viral Vectors
Arnett, A. L. H., Ramos, J. N., & Chamberlain, J. S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381510-1.00076-4 · Cited by 3
Self-citationSystemic RNAi Delivery to the Muscles of ROSA26 Mice Reduces lacZ Expression
Wei, J., & Chamberlain, J. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102053 · Cited by 2
“Also, skeletal muscle specific expression of RNAi expression cassettes will be critical for lowering expression in the heart [43,44].”
BackgroundSelf-citationMckim, D. A., Cripe, T. P., & Cripe, L. H. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.25079 · Cited by 2
“While absolute VC continues to rise, the percentage of ideal or predicted VC (VC%pred) declines in a linear fashion reaching about 80% predicted at age 10.21 Hence, gradually falling VC%pred values include absolute values which occur before, at and following peak VC.”
BackgroundInfluentialIn vitro discovery of novel prokaryotic ion channel candidates for antiarrhythmic gene therapy
Wu, T., Nguyen, H. X., & Bursac, N. (2021) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2021.03.008 · Cited by 2
Bidirectional role of Costameres in the pathophysiology of mdx skeletal muscles
Banks, G. B., Bisset, D., & Chamberlain, J. S. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf127 · Cited by 1
Self-citationHimeda, C. L., Jones, T. I., & Jones, P. L. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101546 · Cited by 2
“(A) Two-vector system: (1) dSpCas9 fused to the KRAB TRD under control of a muscle-specific regulatory cassette (CK8), 22,59 and (2) a DUX4 -targeting sgRNA with dSpCas9-compatible scaffold under control of the U6 promoter.”
Self-citationMcInnes, A., Young, J. N., Aivazian, A. S., Linn, K., Gonzalez, M. A., Cook, S., Vazquez, J., Canzonetta, C., S., P. V. S., & Maselli, R. A. (2025) · Human Gene Therapy · doi:10.1177/10430342251386011 · Cited by 1
Becker, R., Choudhury, P., Oti, M., Fouani, Y., Strobel, B., Ketterer, S., Rumpel, S., Park, J., Kreuz, S., Maier, U., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115469 · Cited by 1
“15,16 These rational designs have marked significant steps forward for gene therapy, beyond the use of strong ubiquitous promoters such as CMV, which can pose the risk for unregulated transgene expression leading to toxicity 17,18 or can be prone to silencing, resulting in a loss of therapeutic…”
Rajendiran, R., Pathak, S., Kumar, A., Bhaumik, S., Amit, S., Pydi, S. P., & Jayandharan, G. R. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01896 · Cited by 1
O’Donohue, A. K., Chu, J., Norris, N., Kao, H.-Y., Yu, J., Lee, L. R., Grimm, D., Gunton, J. E., & Schindeler, A. (2026) · Gene Therapy · doi:10.1038/s41434-026-00636-y · Cited by 1
Metadata
- Authors
- Salva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., Chamberlain, J. S., & Hauschka, S. D.
- Affiliations
- University of Washington (US)
- Corresponding author
- Hauschka, Stephen D
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 15
- Issue
- 2
- Pages
- 320-329
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2065979540
- Cited by
- 232
- References
- 46
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 22 · 2023: 22 · 2022: 11 · 2021: 16 · 2020: 13 · 2019: 12 · 2018: 8 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 7 · 2012: 11
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3536 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R24HL064387)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR018860)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD007183, U54HD047175)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- muscle-specific promoter, muscle creatine kinase, alpha-myosin heavy chain, microdystrophin, mdx mice, skeletal muscle, myocardium, tissue-specific gene expression
- MeSH terms
- Dependovirus, Animals, Cell Line, Cells, Cultured, Cloning, Molecular, Creatine Kinase, Fluorescent Antibody Technique, Gene Expression Regulation, Genetic Vectors, Humans, Male, Mice, Inbred C57BL, Myocardium, Promoter Regions, Genetic, Transfection, Muscle, Skeletal, Ventricular Myosins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.